We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

235 hedge funds and large institutions have $3.22B invested in Array Biopharma Inc in 2018 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 83 increasing their positions, 62 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 20

46% more call options, than puts

Call options by funds: $27.3M | Put options by funds: $18.7M

34% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 62

26% more capital invested

Capital invested by funds: $2.56B → $3.22B (+$660M)

23% more funds holding

Funds holding: 191 → 235 (+44)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

Holders
235
Holders Change
+44
Holders Change %
+23.04%
% of All Funds
5.39%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
66
Increased
83
Reduced
62
Closed
20
Calls
$27.3M
Puts
$18.7M
Net Calls
+$8.62M
Net Calls Change
-$12.9M

Top Buyers

1
FCM
Farallon Capital Management
California
+$49.6M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$39.5M
3
American Century Companies
American Century Companies
Missouri
+$25.4M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$22.8M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
+$19.6M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$84.3M
2
BI
BVF Inc
California
-$58M
3
ACA
Avoro Capital Advisors
New York
-$56.8M
4
O
OrbiMed
New York
-$43.6M
5
Morgan Stanley
Morgan Stanley
New York
-$33.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
American Century Companies
26
American Century Companies
Missouri
$25.9M +$25.4M +1,588,370 New
Morgan Stanley
27
Morgan Stanley
New York
$25.6M -$33.7M -2,106,029 -57%
PAMU
28
Pictet Asset Management (UK)
United Kingdom
$24.2M +$19.6M +1,225,631 +480%
TA
29
Teachers Advisors
New York
$23.6M +$1.98M +123,412 +9%
Two Sigma Advisers
30
Two Sigma Advisers
New York
$21.5M +$1.56M +97,073 +8%
Millennium Management
31
Millennium Management
New York
$19.4M -$26M -1,625,315 -58%
PAM
32
Panagora Asset Management
Massachusetts
$19.3M +$69.6K +4,346 +0.4%
CCI
33
Columbus Circle Investors
$18.5M +$13.4M +838,412 +284%
Citadel Advisors
34
Citadel Advisors
Florida
$18.2M -$3.71M -231,679 -17%
Handelsbanken Fonder
35
Handelsbanken Fonder
Sweden
$18M +$1.12M +70,000 +7%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$17.9M +$1.46M +91,151 +9%
VOYA Investment Management
37
VOYA Investment Management
Georgia
$17.7M +$16M +999,055 +1,149%
TCIM
38
TIAA CREF Investment Management
New York
$17.3M +$3.74M +233,416 +28%
Charles Schwab
39
Charles Schwab
California
$17.2M +$1.49M +92,956 +10%
SAM
40
Sectoral Asset Management
Quebec, Canada
$16.8M +$16.5M +1,031,650 New
PC
41
PointState Capital
New York
$15.9M +$9.03M +563,900 +138%
IBT
42
International Biotechnology Trust
United Kingdom
$13.9M +$5.99M +374,000 +78%
Neuberger Berman Group
43
Neuberger Berman Group
New York
$13.2M +$11.5M +715,000 +747%
Macquarie Group
44
Macquarie Group
Australia
$13.1M +$7.56M +471,825 +143%
KCM
45
Kennedy Capital Management
Missouri
$12.5M +$7.28M +454,279 +147%
RPAM
46
Rhenman & Partners Asset Management
Sweden
$11.4M +$3.18M +198,411 +39%
CAM
47
Cormorant Asset Management
Massachusetts
$10.9M -$501K -31,257 -4%
Axa
48
Axa
France
$9.46M +$3.35M +209,028 +56%
CS
49
Candriam SCA
Luxembourg
$9.38M +$561K +35,000 +6%
SFM
50
Soros Fund Management
New York
$8.59M +$8.43M +526,500 New
1
2
3 4 5

ARRY Hedge Fund Activity: Q1 2018 in Review

235 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2018, worth a combined $3.22B — up 26% from $2.56B a quarter earlier.

Buyers outnumbered sellers: 66 funds opened new ARRY positions and 20 closed out — a net gain of 46 holders — while 83 added to existing stakes and 62 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $49.6M. The largest seller was Point72 Asset Management, cutting an estimated $84.3M.

  • 235 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2018, up from 191 in Q4 2017.
  • Funds reported $3.22B of Array Biopharma Inc stock for Q1 2018, up 26% quarter-over-quarter.
  • 66 funds opened new Array Biopharma Inc positions in Q1 2018 and 20 closed out, a net change of +46 holders.
  • The largest Array Biopharma Inc buyer in Q1 2018 was Farallon Capital Management, an estimated $49.6M added.
  • The largest Array Biopharma Inc seller in Q1 2018 was Point72 Asset Management, an estimated $84.3M sold.

Based on aggregated 13F filings for Q1 2018.